Nerviano, 19, October 2022_NMS Group S.p.A., the largest oncological R&D company in Italy, announced the appointment of Mr. Lincoln Pan to its Board of Directors, effective immediately.

“We are pleased to welcome my PAG colleague Lincoln to the NMS Group Board,” said David Wong, chairman of NMS Group. “Lincoln’s deep experience in increasing the value of our global investments with strong financial oversight will be invaluable to NMS Group as we continue to grow our business.”

Lincoln is a Partner of PAG, the indirect majority shareholder of NMS Group. PAG is a leading APAC-focused alternative investment firm managing over US$50bn in capital. He is co-head of the Private Equity strategy where he leads the non-China investment team and the Operations team and is a member of the Investment Review Committee.  He is also a member of the PAG Group Management Committee.

Lincoln has led many of PAG’s major international investments, including Optimus Group pharmaceuticals, The Cordina Group, Unispace, Edelweiss Wealth Management, Regional Express Airlines, Craveable Brands, Joyson Safety Systems, Cushman & Wakefield and Lexmark International.

Prior to joining PAG, Lincoln was Regional CEO, Greater China for Willis Towers Watson. He previously worked with Advantage Partners, GE Capital, McKinsey & Company and Simpson Thacher & Bartlett. Lincoln holds a JD from Harvard Law School and a BA from Williams College.

Link: 20221019-NMS Group-Lincoln Pan as BoD